Difamilast for Eczema: Reading Adquey's 2026 U.S. Label and Four-Week Trial Results
A new option needs a precise introduction
Difamilast, marketed in the United States as Adquey, is a prescription topical phosphodiesterase 4 inhibitor. The 2026 FDA approval letter covers mild-to-moderate atopic dermatitis in adults and children aged two years and older. That age boundary matters: this is not evidence of suitability for infants, and a new approval is not a promise that every patient will respond.
What the current label calls success
The current prescribing information describes three randomized, double-blind, vehicle-controlled trials totaling 612 treated subjects. The primary assessment was at week four. Success required both clear or almost-clear skin on the Investigator's Global Assessment and at least a two-grade improvement from baseline. Missing scores were counted as failures. This is a defined response threshold, not permanent disease removal.
| Result | What it means |
|---|---|
| Trial 1, multinational | 9/43 (21%) with Adquey versus 1/37 (3%) with vehicle; labeled difference 18 percentage points, 95% CI 5–31. |
| Trial 2, Japan | 70/182 (38%) versus 23/182 (13%); difference 26 points, 95% CI 17–34. |
| Trial 3, Japan, ages 2–14 | 40/85 (47%) versus 15/83 (18%); difference 29 points, 95% CI 15–42. |
Why the trial rows should not become a ranking
The age ranges, countries and participant characteristics differ. The percentages are useful within each randomized comparison, but the highest row does not prove that the medicine works best for that age group. Rounding also means that subtracting the displayed whole-number percentages may not reproduce the label's more precise difference exactly.
These are vehicle comparisons. They do not establish that difamilast is better than another prescription option. A patient choosing between medicines needs information about the actual alternatives, sites involved, tolerability, access and daily routine. Our guide to absolute differences helps make sense of the table without turning a response rate into a cure claim.
Practical label details for a busy household
Adquey is a 1% ointment used topically according to the prescriber's instructions. The label describes twice-daily application, avoidance of infected skin and restrictions against eye, oral or intravaginal use. Nasopharyngitis is the most common listed adverse reaction at or above 1%. A pharmacist can help clarify application sites and how to coordinate the prescription with the rest of the routine. Do not automatically copy another person's treatment plan.
For a baby younger than two, begin with an infant-specific diagnosis and care plan. For any age, record itch as well as visible severity before the review appointment. The four-week response table does not settle every question about an individual's long-term course, and improvement may need ongoing assessment.
Keep the treatment goal explicit
Ask when the clinician expects a useful change, which symptoms should improve and what to do if the skin worsens or appears infected. Consult the AAD guideline hub for broader eczema-care context, while recognizing that newly approved medicines and guideline updates may appear on different timelines. The prescription's current label remains essential.
The separate role of daily moisture care
Dr. Arsy #003 4 oz moisturizer is a cosmetic product for hydration, moisture-barrier support and dry-skin comfort. It is not an eczema medicine, and these studies did not evaluate it. Its sports editorial image does not imply efficacy comparable to a prescription treatment. Discuss product suitability for children or actively inflamed skin with a clinician.
A related evidence question
To see why formulation matters, compare the investigational tofacitinib ointment study; a shared topical route does not make two medicines interchangeable.